

**To:** Manupella, Matthew[Manupella.Matthew@epa.gov]  
**From:** Bloom, Jill  
**Sent:** Tue 4/18/2017 8:11:54 PM  
**Subject:** FW: Q3 Program Review prep--review slides

Hi, Matt. Are you okay with this?

Jill

**From:** Perry, Tracy  
**Sent:** Tuesday, April 18, 2017 3:31 PM  
**To:** Bloom, Jill <Bloom.Jill@epa.gov>  
**Cc:** Walsh, Linsey <Walsh.Linsey@epa.gov>; Manupella, Matthew <Manupella.Matthew@epa.gov>; Schroeder, Carolyn <Schroeder.Carolyn@epa.gov>; Sherman, Kelly <Sherman.Kelly@epa.gov>  
**Subject:** RE: Q3 Program Review prep--review slides

Hi Jill –

For carbaryl, please add the text in red to the slide.

## Ex. 5 - Deliberative Process

I also have suggested edits to methomyl (I know it's not ours, but it is at the same ESA stage, so the text should be the same)

## Ex. 5 - Deliberative Process

**From:** Bloom, Jill

**Sent:** Tuesday, April 18, 2017 3:05 PM

**To:** Biggio, Patricia <[biggio.patricia@epa.gov](mailto:biggio.patricia@epa.gov)>; Dutch, Veronica <[Dutch.Veronica@epa.gov](mailto:Dutch.Veronica@epa.gov)>; Nguyen, Khue <[Nguyen.Khue@epa.gov](mailto:Nguyen.Khue@epa.gov)>; Livingston, Wilhelmena <[Livingston.Wilhelmena@epa.gov](mailto:Livingston.Wilhelmena@epa.gov)>; Jones, Ricardo <[Jones.Ricardo@epa.gov](mailto:Jones.Ricardo@epa.gov)>; Mannix, Marianne <[Mannix.Marianne@epa.gov](mailto:Mannix.Marianne@epa.gov)>; Manupella, Matthew <[Manupella.Matthew@epa.gov](mailto:Manupella.Matthew@epa.gov)>; Piansay, Maria <[Piansay.Maria@epa.gov](mailto:Piansay.Maria@epa.gov)>; Zavala, Miguel A. <[Zavala.Miguel@epa.gov](mailto:Zavala.Miguel@epa.gov)>; Appleyard, Moana <[Appleyard.Moana@epa.gov](mailto:Appleyard.Moana@epa.gov)>; Scheltema, Christina <[Scheltema.Christina@epa.gov](mailto:Scheltema.Christina@epa.gov)>; Newcamp, Caitlin <[Newcamp.Caitlin@epa.gov](mailto:Newcamp.Caitlin@epa.gov)>; Pruitt, Brittany <[Pruitt.Brittany@epa.gov](mailto:Pruitt.Brittany@epa.gov)>; Harty, Thomas <[harty.thomas@epa.gov](mailto:harty.thomas@epa.gov)>; Walsh, Linsey <[Walsh.Linsey@epa.gov](mailto:Walsh.Linsey@epa.gov)>; Gayoso, Jose <[Gayoso.Jose@epa.gov](mailto:Gayoso.Jose@epa.gov)>; Ricciardi, Rachel <[Ricciardi.Rachel@epa.gov](mailto:Ricciardi.Rachel@epa.gov)>

**Cc:** Grable, Melissa <[Grable.Melissa@epa.gov](mailto:Grable.Melissa@epa.gov)>; Jones, RDavid <[Jones.Rdavid@epa.gov](mailto:Jones.Rdavid@epa.gov)>; Friedman, Dana <[Friedman.Dana@epa.gov](mailto:Friedman.Dana@epa.gov)>; Conde, Rosaura <[Conde.Rosaura@epa.gov](mailto:Conde.Rosaura@epa.gov)>; Zinn, Nicole <[Zinn.Nicole@epa.gov](mailto:Zinn.Nicole@epa.gov)>; Perry, Tracy <[Perry.Tracy@epa.gov](mailto:Perry.Tracy@epa.gov)>; Myers, Tom <[Myers.Tom@epa.gov](mailto:Myers.Tom@epa.gov)>; Schroeder, Carolyn <[Schroeder.Carolyn@epa.gov](mailto:Schroeder.Carolyn@epa.gov)>; Biscoe, Melanie <[Biscoe.Melanie@epa.gov](mailto:Biscoe.Melanie@epa.gov)>

**Subject:** RE: Q3 Program Review prep--review slides

Hi everybody. Comments have been trickling in from all corners (our BCs, EFED, HED, CRMs themselves), and Billy has directed me to finalize during the day tomorrow so that Rick can get the (mostly) final package a day in advance. Please have a look and let me know if there are any changes you would like (most recent version attached). As I understand it, RD will present first, then us. If you don't have the meeting invite on your calendar, you may want to ask your BC to forward to you (lest you forget!!!!). Thanks for all your help; you guys ROCK!

Jill

-----Original Appointment-----

**From:** Bloom, Jill

**Sent:** Wednesday, April 05, 2017 11:08 AM

**To:** Bloom, Jill; Biggio, Patricia; Dutch, Veronica; Nguyen, Khue; Livingston, Wilhelmena; Jones, Ricardo; Mannix, Marianne; Manupella, Matthew; Piansay, Maria; Zavala, Miguel A.; Appleyard, Moana; Scheltema, Christina; Newcamp, Caitlin; Pruitt, Brittany; Harty, Thomas

**Cc:** Grable, Melissa; Jones, RDavid; Friedman, Dana; Conde, Rosaura; Zinn, Nicole; Perry, Tracy; Myers, Tom; Jakob, Avivah; Schroeder, Carolyn; Biscoe, Melanie; Arrington, Linda; Sherman, Kelly

**Subject:** Q3 Program Review prep--review slides

**When:** Thursday, April 13, 2017 1:00 PM-2:00 PM (UTC-05:00) Eastern Time (US & Canada).

**Where:** DCRoomPYS9671/Potomac-Yard-One

Reminding CRMs, TLs, and SRAs that we need your text for Program Review slides. Adding Thomas Harty for nitrapyrin.

NOTE: Date/time (and room) change—Requested by folks attending risk assessment training. It is impossible to find time this week that is conflict-free for everyone, but I am proposing this change to accommodate more (not all) participants. This is about the latest we can have this meeting that will still allow us to put slides into a timely review by our Division mgmt. If you can't attend, please make sure that there will be a representative from your Branch that is familiar with your case. Thanks.

Oh—and we still want your slides by Tues. COB, pls.

After the CRMs (with their TLs' blessings) submit their text to me (by Tues. 4/11), we will format them together in powerpoint and then we can review them as a group. In addition to the email below, CRMs with pyrethroids have received guidance from Rosaura on how to present their risk assessment conclusions ("Risk Assessment Issues Identified (Human Health)"). We consider Rosaura's guidance to supercede the email below, for pyrethroids/pyrethrins only. Per Rosaura's request, please copy her and us (Jill and Mel) when you send your text. Thanks.

Jill and Mel

---

**From:** Bloom, Jill

**Sent:** Tuesday, April 04, 2017 3:56 PM

**To:** Biggio, Patricia <[biggio.patricia@epa.gov](mailto:biggio.patricia@epa.gov)>; Dutch, Veronica <[Dutch.Veronica@epa.gov](mailto:Dutch.Veronica@epa.gov)>; Nguyen, Khue <[Nguyen.Khue@epa.gov](mailto:Nguyen.Khue@epa.gov)>; Livingston, Wilhelmena <[Livingston.Wilhelmena@epa.gov](mailto:Livingston.Wilhelmena@epa.gov)>; Jones, Ricardo <[Jones.Ricardo@epa.gov](mailto:Jones.Ricardo@epa.gov)>; Mannix, Marianne <[Mannix.Marianne@epa.gov](mailto:Mannix.Marianne@epa.gov)>; Manupella, Matthew <[Manupella.Matthew@epa.gov](mailto:Manupella.Matthew@epa.gov)>; Piansay, Maria <[Piansay.Maria@epa.gov](mailto:Piansay.Maria@epa.gov)>; Zavala, Miguel A. <[Zavala.Miguel@epa.gov](mailto:Zavala.Miguel@epa.gov)>; Appleyard, Moana <[appleyard.moana@epa.gov](mailto:appleyard.moana@epa.gov)>; Scheltema,

Christina <Scheltema.Christina@epa.gov>; Newcamp, Caitlin <Newcamp.Caitlin@epa.gov>;  
Pruitt, Brittany <Pruitt.Brittany@epa.gov>  
**Cc:** Grable, Melissa <Grable.Melissa@epa.gov>; Jones, RDavid <Jones.Rdavid@epa.gov>;  
Friedman, Dana <friedman.dana@epa.gov>; Conde, Rosaura <Conde.Rosaura@epa.gov>; Zinn,  
Nicole <Zinn.Nicole@epa.gov>; Perry, Tracy <Perry.Tracy@epa.gov>; Myers, Tom  
<Myers.Tom@epa.gov>; Jakob, Avivah <Jakob.Avivah@epa.gov>; Schroeder, Carolyn  
<Schroeder.Carolyn@epa.gov>; Biscoe, Melanie <Biscoe.Melanie@epa.gov>; Arrington, Linda  
<arrington.linda@epa.gov>  
**Subject:** Q3 Program Review is scheduled for 4/20 and we need your help

Hi everybody—

It's that time again (!) to get our presentations together for Program Review. For the first month in the quarter, we will present on DRAs. I have attached the list of chemicals that should be included for FY17Q3, along with their CRM caretakers (let me know if you see any errors, please). I know that some of you may not have anything in writing yet from your EFED and HED teams. In those cases, please work with your team to identify risks of concern as best you can. Billy has said that the focus should be on the general risk picture and not necessarily on specific numbers. We need just one slide for each chemical.

Please use this general format:

- Background
- Risk Assessment Issues Identified (human health, and ecological if appropriate)
- Path forward

Please use Garamond font. Please draft in Word—we will convert to slides later (it is easier to do track changes in Word).

You should be able to develop the background and path forward sections yourselves:

- Background—what type of pesticide (e.g., insecticide), chemical family (e.g., pyrethroid), major use sites (are there residential uses?)

- Path forward—are we on track to get the risk assessment before the projected publication date?

The “Risk Assessment Issues Identified” section may include:

(Obviously) risks of concern

Are the assessments qualitative or quantitative?

Is the assessment *de minimis*? Are we able to make a no effect finding for listed species?

Level of refinement of risk assessment

Risk drivers

Are there lots of incidents?

Important future data needs (like pollinators)

ESA issues, if any

It appears from the attached presentation (from January) that we briefed mgmt on some of these already:

- Gamma and lambda cyhalothrin (HHRA only)
- Esfenvalerate (HH)
- Etofenprox (HH)
- Cyfluthrins (HH)
- Pyrethrins (HH)
- Methomyl
- Phostebupirim
- Pendimethalin
- EPTC

- Imidacloprid (HH)

You may be able to build on what was presented then.

Please send your draft text to Jill and Melanie by next Tuesday (4/11). Please have your team leader/SRA review before you send it to us. Many, many thanks.

Jill and Melanie